Piscataway, NJ, March 9, 2023– Camber Pharmaceuticals is pleased to announce the addition of Linezolid for Oral Suspension to its current portfolio.
Linezolid for Oral Suspension is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and resistant isolates) or Streptococcus pneumoniae.
Linezolid for Oral Suspension is available in 100 mg/5 mL strength and supplied in 150 mL bottle.
To find out more about Linezolid for Oral Suspension please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]
